Plexus Partners with BioSig to Manufacture PURE EP™ Signal Processing System

https://cdn.pcbdirectory.com/news/BioSig_Featured_637685954405816987.jpg712370

BioSig Technologies, a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, has announced that the Company entered into a manufacturing and professional services agreement with Plexus.

Headquartered in Neenah, Wisconsin, Plexus counts healthcare and life sciences as one of its largest market sectors representing nearly 40% of annual revenue. Under the terms of the newly reached agreement, Plexus will bring to market the PURE EP™ System, the Company’s signal processing technology for arrhythmia care, and develop a new product pipeline for BioSig’s subsidiary NeuroClear Technologies.

“We are fundamentally proud to partner with Plexus on our mission to advance therapies through technological innovation. Their engineering and manufacturing capabilities and outstanding expertise in building complex medical devices make Plexus a foundational cornerstone to support BioSig’s growth objectives now and well into the future. The recent release of our clinical data has increased physician interest in our technology. We believe that the post-pandemic recovery in elective procedures will further drive our installation footprint, and we are confident that Plexus’ first-class operational infrastructure will ensure a quality supply of the PURE EP™ systems to meet growing market needs,” commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.

“We are proud to partner with BioSig in helping to bring their PURE EP™ System to market. The PURE EP™ System is an innovative, breakthrough device that will greatly improve healthcare opportunities for physicians and patients alike. Through this partnership, we look forward to furthering our vision of helping create the products that build a better world,” commented Michael Tendick, Vice President – Healthcare and Life Sciences Market Sector, Plexus Corp.

The PURE EP™ is an FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology. To date, over 60 physicians have completed over 1300 patient cases with the PURE EP™ System across twelve clinical sites.

The Company recently completed its first multi-centered, prospective clinical trial and presented preliminary clinical data during the annual Heart Rhythm 2021 convention in July in Boston, MA.

The Company is in a focused commercial launch of the PURE EP™ System in the Northeast, Texas, and Florida and counts some of the country’s leading centers of excellence, including the Mayo Clinic in Rochester, MN, and St. David’s Medical Center in Austin, TX, among its customers.

Click here to know more about PURE EP solution.